Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in Contract Development and Manufacturing Organization (CDMO) services for next-generation pharmaceuticals, has signed a Memorandum of Understanding (MOU) with Nippon Fine Chemical Co., Ltd., and its Taiwan subsidiary, Zillion Fine Chemicals International Co., Ltd. The three parties aim to deepen collaboration in the field of nanoparticle-based drug CDMO manufacturing while expanding their presence in Taiwan, Japan, and international CDMO markets.

Through this partnership, Amaran Biotech will utilize its aseptic filling line and CDMO services to support Nippon Fine Chemical’s production of nanoparticle-based drugs, including liposomes and lipid nanoparticles (LNPs).

The services provided will include sterile filtration, aseptic filling, packaging, storage, and quality management. The collaboration also extends to Zillion Fine Chemicals’ CDMO operations in Taiwan, with the three parties working together to complement each other’s strengths and upgrade the technology and services of the CDMO markets in Taiwan, Japan, and beyond.

Ryan Lo, Vice President of Corporate Strategy, Business Development & Regulatory Affairs, Amaran Biotech, said, “Amaran’s industry-leading aseptic filling line and extensive experience in pharmaceutical production have earned Nippon Fine Chemical’s trust. This collaboration not only provides a more comprehensive solution for nanoparticle-based drug CDMO but also aims to create synergistic business opportunities that multiply the value of our efforts.”

Masaki Matsumoto, Senior General Manager of Nippon Fine Chemical, added: “The nanoparticle-based drug market holds tremendous growth potential. We believe this partnership will inject significant momentum into our CDMO business development in Japan, Taiwan, and the global market.”

Related Insights

Read about CDMO industry trends in 2025.